EP0944584A1 - Benzamidoaldehyde und deren anwendung als inhibitoren von cystein-proteasen - Google Patents

Benzamidoaldehyde und deren anwendung als inhibitoren von cystein-proteasen

Info

Publication number
EP0944584A1
EP0944584A1 EP97951172A EP97951172A EP0944584A1 EP 0944584 A1 EP0944584 A1 EP 0944584A1 EP 97951172 A EP97951172 A EP 97951172A EP 97951172 A EP97951172 A EP 97951172A EP 0944584 A1 EP0944584 A1 EP 0944584A1
Authority
EP
European Patent Office
Prior art keywords
phenyl
benzamide
mmol
product
propan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97951172A
Other languages
German (de)
English (en)
French (fr)
Inventor
Wilfried Lubisch
Achim Möller
Hans-Jörg Treiber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of EP0944584A1 publication Critical patent/EP0944584A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/76—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/42—Y being a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the present invention relates to new benzamido aldehydes and their use in combating diseases.
  • Calpains are intracellular, proteolytic enzymes from the group of so-called cysteine proteases and are found in many cells. Calpains are activated by increased calcium concentration, with a distinction between Calpain I or ⁇ -calpain, which is activated by ⁇ -molar concentrations of calcium ions, and Calpain II or m-calpain, which is activated by m-molar concentrations of calcium ions , distinguishes (P.Johnson,
  • calpains play an important role in various physiological processes. These include: cleavages of regulatory proteins - such as protein kinase C, cytoskeleton proteins (such as MAP 2 and spectrin), muscle proteins, proteins in the activation of platelets, proteins in mitosis and others which are described in. MJBarrett et al . , Life Be. 1991, 48, 1659-69 and K.K. ang et al., Trends in Pharmacol. Sei. , 1994, 15, 412-9; Protein breakdown in rheumatoid arthritis and neuropeptide metabolism.
  • regulatory proteins such as protein kinase C, cytoskeleton proteins (such as MAP 2 and spectrin)
  • muscle proteins proteins in the activation of platelets
  • proteins in mitosis proteins in mitosis and others which are described in. MJBarrett et al . , Life Be. 1991, 48, 1659-69 and K.K. ang et al.,
  • Increased calpain levels were measured in various pathophysiological processes, for example: ischemia of the heart (e.g. heart attack), the kidney or the central nervous system (e.g. "stroke"), inflammation, muscular dystrophies, eye cataracts, injuries to the central nervous system (e.g. Jardina) and Alzheimer's disease (see KK ang, above). Therefore, one suspects one to ⁇ these diseases connexion with increased intracellular calcium levels. This calcium-dependent processes überakti ⁇ be archived and is no longer subject to physiological regulation. Accordingly, overactivation of calpains can also trigger pathophysiological processes.
  • Calpain inhibitors have already been described in the literature 25. However, these are predominantly either irreversible or peptide inhibitors. Irreversible inhibitors are generally alkylating substances and have the disadvantage that they react unselectively in the organism or are unstable. For example, these inhibitors often show undesirable side effects such as toxicity and are therefore restricted in use or unusable.
  • the irreversible inhibitors include, for example, the epoxides E 64 (EBMcGowan et al., Biochem.Biophys .Res .Commun. 1989, 158, 432-5), ⁇ -haloketones (H. Angliker et al., J.Med. Che. 1992, 35, 216-20) and disulfides (R. Matsueda et al., 35 Che. Lat. 1990, 191-194).
  • cysteine proteases such as calpain
  • peptide aldehydes or ketones especially dipeptide and tripepidic aldehydes
  • dipeptide and tripepidic aldehydes such as
  • JP 8183759, JP 8183769, JP 8183771 and EP 520336 have described aldehydes derived from dipeptides, with saturated carbocyclic rings, for example cyclohexanes, or saturated heterocyclic rings, for example piperidines, being incorporated into these peptic inhibitors instead of an amino acid which gave novel calpain inhibitors.
  • the present invention relates to benzamido aldehydes of formula 45 and their tautomeric and isomeric forms, and optionally their physiologically tolerable salts, in which the variables have the following meaning:
  • R 1 phenyl, naphthalene, quinoline, isoquinoline, tetrahy ⁇ roquinoline, tetrahydroisoquinoline, pyridine, pyrimidine, pyrazine, pyridazine, quinazoline, quinoxaline, thiophene, benzochiophene, benzofuran, furan or indole, the aromatic and heteroaromatic rings through up to three aromatic rings R 4 may be substituted ",
  • R 2 is hydrogen, chlorine, bromine, fluorine, phenyl, a phenyl which is optionally substituted by a C 1 -C 4 -hydrocarbon radical, -NHCO-C ⁇ -C 4 -alkyl, -NHCOPh, -NHCO-naphthyl, -NHS0 2 -C 1- 4 -alkyl, CONH 2 , COOH, -COO-C ⁇ - 4 alkyl, -O-C ⁇ - 4 alkyl, -CO-NH-C ⁇ - 4 alkyl, N0 2 or NH 2 ,
  • R 3 is a " -CC 6 hydrocarbon radical, which is also a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
  • X is a bond, - (CH 2 ) m -, - (CH 2 ) m -0- (CH 2 ) o ⁇ ⁇
  • n is the number 1 or 2
  • n is the number 0, 1, 2, 3 or 4 and
  • the compounds of formula I can be used as racemates or as enantiomerically pure compounds or as diastereomers. If enantiomerically pure compounds are desired, these can be obtained, for example, that one carries out with a suitable optically active base or acid is a classical racemate cleavage with the compounds of the formula I or their products between ⁇ . On the other hand, the enantiomeric compounds can also be produced by using commercially available compounds, for example optically active amino acids.
  • the invention also relates to compounds of the formula I mesomeric or tautomeric compounds, for example those in which the keto group of the formula I is present as an enol tautomer.
  • the new compounds I can contain a basic or an acidic group.
  • the compounds can be in the form of their physiologically tolerable salts, which can be obtained by reacting the compounds with a suitable acid or base.
  • acids examples include hydrochloric acid, citric acid, tartaric acid, lactic acid, phosphoric acid, acetic acid, formic acid, maleic acid, fumaric acid, malic acid, succinic acid, malonic acid, sulfuric acid, methanesulfonic acid and toluenesulfonic acid.
  • Sodium hydroxide, potassium hydroxide, ammonia and simple organic amines are particularly suitable as bases.
  • benzamido aldehydes of the formula I in which R 2 is hydrogen, -CC 4 -alkyl, fluorine, chlorine or bromine, R 3 CH 2 -phenyl, which may be substituted by R 4 , and R 1 -, X , n, m, and o have the meanings given above.
  • benzamidoaldehydes I can be prepared in various ways, which are outlined in the following synthesis scheme. Synthesis scheme
  • Benzoic acid derivatives II are combined with suitable amino alcohols III to give the corresponding benzamido aldehydes IV.
  • Usual peptide coupling methods are used, which are described, for example, in CRLarock, Comprehensive Organic Transformations, VCH Publishers, 1989, page 972f. or in Houben-Weyl, Methods of Organic Chemistry, 4th edition, E5, Kap.V. It is preferred to work with "activated” acid derivatives of II, the acid group COOH being converted into a group COL.
  • L represents a leaving group such as Cl, imidazole and N-hydroxybenzotriazole. This activated acid is then reacted with amines to give the amides IV.
  • the reaction takes place in anhydrous, inert solvents such as methylene chloride, tetrahydrofuran and dimethylformamide at temperatures from -20 to + 25 ° C.
  • These alcohol derivatives IV can be oxidized to the aldehyde derivatives I according to the invention.
  • Various customary oxidation reactions can be used for this (see CRLarock, Comprehensive Organic Transformations, VCH Publisher, 1989, page 604 f.) Such as Swern- and Swern-analogous oxidations (TTTidwell, Synthesis 1990, 857-70), sodium hypochlorite / TEMPO (S L.Harbenson et al., See above) or the Dess-Martin reagent (J.Org.Chem.
  • inert aprotic solvents such as dimethylformamide, tetrahydrofuran or methylene chloride with oxidizing agents such as DMSO / pyridine x SO 3 or DMSO / oxalyl chloride at temperatures from -50 to + 25 ° C., depending on the method (see literature above).
  • benzoic acid II can be reacted with aminohydroxamic acid derivatives VI to give benzamidoaldehydes I.
  • the same reaction procedure is used as for the preparation of IV.
  • the hydroxam derivatives VI can be obtained from the protected amino acids V by conversion with a hydroxylamine.
  • the amide production processes already described are also used here.
  • the protective group for example Boc, is cleaved off in the customary manner, for example using trifluoroacetic acid.
  • the benzamide-hydroxamic acids VII thus obtained can be converted into the aldehydes I according to the invention by reduction.
  • lithium aluminum hydride is used as a reducing agent at temperatures from -60 to 0 ° C in inert solvents such as tetrahydrofuran or ether.
  • the benzamido aldehydes I are inhibitors of cysteine proteases such as calpain I and II as well as cathepsin B and L and can thus be used to combat diseases which are associated with an increased enzyme activity of the calpain enzymes and / or cathepsin enzymes.
  • the present Benzamidoaldehyde I can then be used to treat neurodegenerative diseases according to
  • Ischemia, trauma, subarachnoid hemorrhage and / or stroke occur, and / or of neurodegenerative diseases such as multiple infarct dementia, Alzheimer's disease and / or Huntington's disease and / or continue to treat damage to the heart after cardiac ischemia, damage to the Kidneys after renal ischemia, skeletal muscle damage, muscular dystrophy, damage caused by smooth muscle cell proliferation arise, serve coronary vasospasm, cerebral vasospasm, cataracts of the eyes and / or restenosis of the bloodstream after angioplasty.
  • neurodegenerative diseases such as multiple infarct dementia, Alzheimer's disease and / or Huntington's disease and / or continue to treat damage to the heart after cardiac ischemia, damage to the Kidneys after renal ischemia, skeletal muscle damage, muscular dystrophy, damage caused by smooth muscle cell proliferation arise, serve coronary vasospasm, cerebral vasospasm, cataracts of the eyes and / or restenosis of the bloodstream after
  • the benzamido aldehydes I can be useful in the chemotherapy of tumors and their metastasis 5 and / or for the treatment of diseases in which an increased level of interleukin-1 occurs, such as inflammation and / or rheumatic diseases.
  • the benzamido aldehydes I were measured in this way for their inhibitory effect on calpain I, calpain II and cathepsin B.
  • Cathepsin B inhibition was determined analogously to a method by S.Hasnain et al., J.Biol.Chem. 1993, 268, 235-40. To 88 ⁇ L Cathep
  • calpain inhibitors The inhibitory properties of calpain inhibitors are tested in buffer with 50 mM Tris-HCl, pH 7.5; 0.1 M NaCl; 1 mM dithiotreithol: 0.11 mM CaCl 2 , the fluorogenic calpain
  • tyrosine kinase pp60src was cleaved by calpain. This was done by Oda et al. in J. Biol. Chem., 1993, Vol 268, 12603-12608. It was shown that the cleavage of pp60src can be prevented by calpeptin, an inhibitor for calpain. Based on this publication, the cellular effectiveness of the new substances was tested. Fresh human blood with citrate was centrifuged at 200 g for 15 min.
  • the platelet-rich plasma was pooled and diluted 1: 1 with platelet buffer (platelet buffer: 68 mM NaCl, 2.7 mM KC1, 0.5 mM MgCl 2 ⁇ 6 H 2 O, 0.24 mM NaH 2 PO 4 ⁇ H 2 0, 12 mM NaHC0 3 , 5, 6 mM glucose, 1 mM EDTA, pH 7.4). After a centrifugation and washing step with platelet buffer, the platelets were adjusted to 10 7 cells / ml. The human platelets were isolated at RT.
  • test mixture isolated platelets (2 ⁇ 10 6 ) with different concentrations of inhibitors (dissolved in DMSO) were preincubated for 5 min at 37 ° C. The platelets were then activated with 1 ⁇ M Ionophore A23187 and 5 mM CaCl 2 . After 5 minutes of incubation, the platelets were briefly centrifuged at 13,000 rpm and the pellet was taken up in SDS sample buffer (SDS sample buffer: 20 mM Tris-HCl, 5 mM EDTA, 5 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 5 ⁇ g / ml leupeptin, 10 ⁇ m pepstatin, 10% glycerol and 1% SDS).
  • SDS sample buffer 20 mM Tris-HCl, 5 mM EDTA, 5 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 5 ⁇ g / ml leupeptin, 10 ⁇ m pep
  • the proteins were separated in a 12% gel and pp60src and its 52-kDa and 47-kDa cleavage products were identified by Western blotting.
  • the polyclonal rabbit antibody Anti-Cys-src (pp60 c " src ) used had been purchased from Biomol Fine Chemicals (Hamburg). This primary antibody was detected with a goat HRP-coupled second antibody (Boehringer Mannheim, FRG) Western blotting was carried out according to known methods.
  • the cleavage of pp60src was quantified densitometrically, using controls which had not been activated (control 1: no cleavage) and plates treated with ionophore and calcium (control 2: corresponds to 100% cleavage).
  • the STP 5 o-value is the concentration of inhibitor at which the intensity of the color reaction of the 60-kDa band of control 1 plus control 2 divided value corresponding to the intensity by the second
  • the Tes' t was analogous to Choi DW, Maulucci-Gedde MA and war Stein AR (1987) "Glutamate neurotoxicity in cortical cell culture", J. Neurosci. 7, 357-368.
  • the cortex halves were prepared from 15-day-old mouse embryos and the individual cells were obtained enzymatically (trypsin). These cells (glia and cortical neurons) were sown in 24 well plates. After three days (laminin-coated plates) or seven days (ornithine-coated plates), mitosis treatment was carried out with FDU (5-fluoro-2-deoxyuridine). 15 days after the cell preparation, cell death was triggered by adding glutamate (15 min). After the glutamate has been removed, the calpamine inhibitors are added. 24 hours later, cell damage was determined by determining lactate dehydrogenase (LDH) in the cell culture supernatant.
  • LDH lactate dehydrogenase
  • cell death can be triggered by calcium in the presence of the ionophore A23187.
  • 10 5 cells / well were plated in microtiter plates 20 h before the experiment. After this period, the cells were incubated with various concentrations of inhibitors in the presence of 2.5 ⁇ M ionophore and 5 mM calcium.
  • the Reakti ⁇ onsansatz After 5 h, 0.05 ml of XTT (Cell Proliferation Kit II, Boehringer Mannnheim) added.
  • the optical density was determined approximately 17 hours later, according to the manufacturer's instructions, in the Easy Reader EAR 400 from SLT. The optical density at which half of the cells died is calculated from the two controls with cells without inhibitors which were incubated in the absence and presence of ionophore.
  • a number of neurological diseases or mental disorders result in increased glutamate activity, which leads to states of overexcitation or toxic effects in the central nervous system (CNS).
  • CNS central nervous system
  • Glutamate antagonists including in particular NMDA antagonists or their modulators and the AMPA antagonists, are suitable for therapeutic use as agents against neurodegenerative diseases (Huntington's and Parkinson's diseases), neurotoxic disorders after hypoxia, anoxia or Ischemia, as it occurs after "Stroke”, or also as anti-epileptics, antidepressants and anxiolytics (cf. Medicinal Research 1990, 40, 511 - 514; TIPS, 1990, 11, 334 - 338 and Drugs of the Future 1989, 14 (11), 1059-1071).
  • EAA Excitatory Amino Acids
  • calpain inhibitors in cell cultures also have a protective action against cell death caused by EAA (H. Cauer et al., Brain Research 1993, 607, 354-356; Yu Cheg and AY Sun, Neurochem. Res 1994, 19, 1557-1564).
  • EAA eg NMDA or AMPA
  • the calpain inhibitors contained in this application are surprisingly effective even against the cramps caused by EAA (eg NMDA or AMPA) and show that with a therapeutic use in the above-mentioned CNS diseases.
  • the pharmaceutical preparations according to the invention contain a therapeutically effective amount of the compounds I.
  • the active ingredients can be contained in the usual concentrations.
  • the active substances are contained in an amount of 0.001 to 1% by weight, preferably 0.01 to 0.1% by weight.
  • the preparations are administered in single doses. 0.1 to 100 mg per kg body weight are given in a single dose.
  • the preparation can be administered daily in one or more doses depending on the type and severity of the diseases.
  • the pharmaceutical preparations according to the invention contain, in addition to the active ingredient, the customary carriers and diluents.
  • pharmaceutical technical auxiliaries such as ethanol, isopropanol, ethoxylated castor oil, ethoxylated hydrogenated castor oil, polyacrylic acid, polyethylene glycol, polyethylene glycol stearate, ethoxylated fatty alcohols, paraffin oil, petroleum jelly and wool fat, can be used.
  • Milk sugar, propylene glycol, ethanol, starch, talc and polyvinylpyrrolidone are suitable for internal use.
  • Antioxidants such as tocopherol and butylated hydroxyanisole and butylated hydroxytoluene, taste-improving additives, stabilizers, emulsifiers and lubricants can also be present.
  • the substances contained in the preparation in addition to the active ingredient and the substances used in the manufacture of the pharmaceutical preparations are toxicologically harmless and compatible with the respective substance.
  • the pharmaceutical preparations are produced in a customary manner, for example by mixing the active ingredient with other customary excipients and diluents.
  • the pharmaceutical preparations can be administered in various modes of administration, for example orally, parenterally and intravenously by infusion, subcutaneously, intraperitoneally and topically.
  • Formulations like tablets, emulsions, Infusion and injection solutions, pastes, ointments, gels, creams, lotions, powders and sprays possible.
  • Triethylamine dissolved in 50 ml of anhydrous tetrahydrofuran, 0.8 g (7.7 mmol) of ethyl chloroformate, dissolved in a little tetrahydrofuran, was added dropwise at 0.degree. Subsequently
  • the product was made from 5g analogously to the instruction la
  • Tetrahydrofuran was added to 9 g (56 mmol) of carbonyldiimidazole and everything was boiled under reflux for 1 h. After that you gave

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
EP97951172A 1996-11-26 1997-11-11 Benzamidoaldehyde und deren anwendung als inhibitoren von cystein-proteasen Withdrawn EP0944584A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19648793A DE19648793A1 (de) 1996-11-26 1996-11-26 Neue Benzamide und deren Anwendung
DE19648793 1996-11-26
PCT/EP1997/006292 WO1998023581A1 (de) 1996-11-26 1997-11-11 Benzamidoaldehyde und deren anwendung als inhibitoren von cystein-proteasen

Publications (1)

Publication Number Publication Date
EP0944584A1 true EP0944584A1 (de) 1999-09-29

Family

ID=7812713

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97951172A Withdrawn EP0944584A1 (de) 1996-11-26 1997-11-11 Benzamidoaldehyde und deren anwendung als inhibitoren von cystein-proteasen

Country Status (26)

Country Link
US (1) US6251917B1 (cs)
EP (1) EP0944584A1 (cs)
JP (1) JP2001506596A (cs)
KR (1) KR20000057227A (cs)
CN (1) CN1238761A (cs)
AR (1) AR010062A1 (cs)
AU (1) AU742262B2 (cs)
BG (1) BG103433A (cs)
BR (1) BR9713147A (cs)
CA (1) CA2272388A1 (cs)
CO (1) CO4910162A1 (cs)
CZ (1) CZ183399A3 (cs)
DE (1) DE19648793A1 (cs)
HR (1) HRP970637A2 (cs)
HU (1) HUP0000427A3 (cs)
ID (1) ID21781A (cs)
IL (1) IL129603A0 (cs)
NO (1) NO992492D0 (cs)
NZ (1) NZ335542A (cs)
PL (1) PL333505A1 (cs)
RU (1) RU2189973C2 (cs)
SK (1) SK56599A3 (cs)
TR (1) TR199901191T2 (cs)
UA (1) UA51753C2 (cs)
WO (1) WO1998023581A1 (cs)
ZA (1) ZA9710569B (cs)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100509388B1 (ko) 1996-10-18 2005-08-23 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
ATE346035T1 (de) 1998-03-31 2006-12-15 Vertex Pharma Inhibitoren von serin proteasen, insbesondere von hepatitis c virus ns3 protease
WO1999054320A1 (de) * 1998-04-20 1999-10-28 Basf Aktiengesellschaft Neue heterocyclisch substituierte amide mit cystein-protease hemmender wirkung
GB9903861D0 (en) * 1999-02-20 1999-04-14 Zeneca Ltd Chemical compounds
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
DE10021246A1 (de) * 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
CA2413878A1 (en) * 2000-06-20 2001-12-27 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
WO2002040021A2 (en) 2000-11-17 2002-05-23 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
DE10114762A1 (de) * 2001-03-26 2002-10-02 Knoll Gmbh Verwendung von Cysteinprotease-Inhibitoren
IL162533A0 (en) 2001-12-19 2005-11-20 Atherogenics Inc Chalcone derivatives and their use to treat diseases
US7173129B2 (en) 2003-06-06 2007-02-06 Athero Genics, Inc. Sulfonamide-substituted chalcone derivatives and their use to treat diseases
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
US7423176B2 (en) * 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
MXPA06011555A (es) 2004-05-04 2006-12-15 Pfizer Compuestos de metil-aril o heteroaril-amida sustituida.
SE0401342D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019832A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
US7569725B2 (en) 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
KR20080031379A (ko) * 2005-07-11 2008-04-08 와이어쓰 글루타메이트 아그레카나제 저해제
US8247556B2 (en) * 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
US20110112193A1 (en) * 2008-05-14 2011-05-12 Peter Nilsson Bis-aryl compounds for use as medicaments
EA022417B1 (ru) * 2008-10-21 2015-12-30 Саймабэй Терапевтикс, Инк. Арильные агонисты рецептора gpr120 и их применение
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US9701627B2 (en) * 2014-06-16 2017-07-11 University Of Maryland, Baltimore LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
EP3426674A4 (en) 2016-03-09 2019-08-14 Blade Therapeutics, Inc. CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2018064119A1 (en) 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2018097999A1 (en) * 2016-11-23 2018-05-31 The Regents Of The University Of California Compositions and methods for modulating protease activity
CA3067063A1 (en) * 2017-06-23 2018-12-27 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
CN118103038A (zh) * 2021-08-20 2024-05-28 英安塔制药有限公司 17β-羟基类固醇脱氢酶13型抑制剂及其使用方法
CN113999832A (zh) * 2021-11-30 2022-02-01 上海市农业科学院 草菇子实体中性蛋白酶、提取纯化方法及其应用
CN114292833A (zh) * 2021-11-30 2022-04-08 上海市农业科学院 从草菇子实体中提取纯化蛋白酶的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3971787A (en) * 1973-02-05 1976-07-27 John Wyeth & Brother Limited (4-Quinolylamino)benzamides
US4957533A (en) * 1987-10-26 1990-09-18 Eli Lilly And Company N-phenylalkylbenzamide fungicides
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
WO1992012140A1 (en) 1990-12-28 1992-07-23 Georgia Tech Research Corporation Peptides ketoamides, ketoacids, and ketoesters
CA2071621C (en) 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
AU3592493A (en) 1992-01-13 1993-08-03 Smithkline Beecham Corporation Pyridyl substituted imidazoles
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
NZ274074A (en) 1993-10-01 1997-11-24 Merrell Pharma Inc Various dipeptide derivatives having a reduced carboxy group, the aldehyde being optionally substituted; pharmaceutical compositions
CA2221684A1 (en) * 1995-06-06 1996-12-12 Athena Neurosciences, Inc. Novel cathepsin and methods and compositions for inhibition thereof
US5849711A (en) * 1995-06-06 1998-12-15 Athena Neurosciences, Inc. Cathepsin and methods and compositions for inhibition thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9823581A1 *

Also Published As

Publication number Publication date
CN1238761A (zh) 1999-12-15
AU5481498A (en) 1998-06-22
US6251917B1 (en) 2001-06-26
KR20000057227A (ko) 2000-09-15
RU2189973C2 (ru) 2002-09-27
NO992492L (no) 1999-05-25
BG103433A (bg) 2000-02-29
HRP970637A2 (en) 1998-10-31
JP2001506596A (ja) 2001-05-22
NO992492D0 (no) 1999-05-25
SK56599A3 (en) 1999-11-08
CZ183399A3 (cs) 1999-08-11
HUP0000427A2 (hu) 2000-05-28
DE19648793A1 (de) 1998-05-28
NZ335542A (en) 2000-07-28
BR9713147A (pt) 2000-02-08
AR010062A1 (es) 2000-05-17
CO4910162A1 (es) 2000-04-24
UA51753C2 (uk) 2002-12-16
IL129603A0 (en) 2000-02-29
CA2272388A1 (en) 1998-06-04
HUP0000427A3 (en) 2001-09-28
ZA9710569B (en) 1999-05-25
WO1998023581A1 (de) 1998-06-04
TR199901191T2 (xx) 1999-12-21
PL333505A1 (en) 1999-12-20
AU742262B2 (en) 2001-12-20
ID21781A (id) 1999-07-22

Similar Documents

Publication Publication Date Title
EP0944584A1 (de) Benzamidoaldehyde und deren anwendung als inhibitoren von cystein-proteasen
EP0944582B1 (de) Ketobenzamide als calpain-inhibitoren
EP1082308B1 (de) Heterocyclisch substituierte amide als calpainhemmer
EP1073638B1 (de) Heterozyklische substituierte amide, deren herstellung und anwendung
EP1073641B1 (de) Neue substituierte amide, deren herstellung und anwendung
EP0946509A1 (de) Neue heterocyclisch substituierte benzamide und deren anwendung bei der bekämpfung von krankheiten
DE19817461A1 (de) Neue substituierte Benzamide, deren Herstellung und Anwendung
EP1080074B1 (de) Heterocyclische substituierte Amide, deren Herstellung und Verwendung
EP1073631A1 (de) Neue substituierte amide, deren herstellung und anwendung
EP0934273A1 (de) Neue piperidin-ketocarbonsäure-derivate, deren herstellung und anwendung
EP1080083A1 (de) Neue heterocyclisch substituierte amide mit cystein-protease hemmender wirkung
MXPA99004555A (en) Benzamidoaldehydes and their use as cysteine protease inhibitors
CZ20003867A3 (cs) Amidy a jejich použití
MXPA00009969A (en) New substituted amides, their production and their use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990420

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: RO PAYMENT 19990420;SI PAYMENT 19990420

17Q First examination report despatched

Effective date: 20011205

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBOTT GMBH & CO. KG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040602